At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 106 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
vildagliptin 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Dipeptidyl Peptidase (DPP) IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Patients With Type 2 Diabetes
In Brief
A Phase 4 clinical trial evaluating Placebo and vildagliptin for Chronic Foot Ulcers. Completed, enrolled 106 participants across 1 site.
Detailed Summary
A randomized versus placebo trial designed to evaluate the clinical and humoral effects of 4 months of vildagliptin on healing of chronic ulcers in type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Foot Ulcers
CountriesItaly
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2011
First PostedNov 2011
Primary CompletionJan 2016
TodayJul 2026
First PostedNov 16, 2011
Enrollment StartMay 1, 2011
Primary CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 14.6 years ago
Interventions
Placebodrug
Placebo is added to the standard good medical practice. Plus Metformin and/or Sulfonylurea
vildagliptindrug
50 mg per os b.i.d. for 4 months of treatment, added to the standard good medical practice.Plus Metformin and/or Sulfonylurea